Nature Communications (May 2021)

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens

  • Nicholas D. Walter,
  • Sarah E. M. Born,
  • Gregory T. Robertson,
  • Matthew Reichlen,
  • Christian Dide-Agossou,
  • Victoria A. Ektnitphong,
  • Karen Rossmassler,
  • Michelle E. Ramey,
  • Allison A. Bauman,
  • Victor Ozols,
  • Shelby C. Bearrows,
  • Gary Schoolnik,
  • Gregory Dolganov,
  • Benjamin Garcia,
  • Emmanuel Musisi,
  • William Worodria,
  • Laurence Huang,
  • J. Lucian Davis,
  • Nhung V. Nguyen,
  • Hung V. Nguyen,
  • Anh T. V. Nguyen,
  • Ha Phan,
  • Carol Wilusz,
  • Brendan K. Podell,
  • N’ Dira Sanoussi,
  • Bouke C. de Jong,
  • Corinne S. Merle,
  • Dissou Affolabi,
  • Helen McIlleron,
  • Maria Garcia-Cremades,
  • Ekaterina Maidji,
  • Franceen Eshun-Wilson,
  • Brandon Aguilar-Rodriguez,
  • Dhuvarakesh Karthikeyan,
  • Khisimuzi Mdluli,
  • Cathy Bansbach,
  • Anne J. Lenaerts,
  • Radojka M. Savic,
  • Payam Nahid,
  • Joshua J. Vásquez,
  • Martin I. Voskuil

DOI
https://doi.org/10.1038/s41467-021-22833-6
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

It is unclear why different antibiotics vary in their ability to shorten treatment of tuberculosis. Here, the authors show that a measure based on ribosomal RNA synthesis in Mycobacterium tuberculosis correlates with treatment shortening in culture, in mice and in human studies.